| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/23/2026 | ±2.8% | -2.6% | over-priced |
| 01/29/2026 | ±4.9% | +3.6% | over-priced |
| 10/24/2025 | ±4.2% | +2.8% | over-priced |
| 04/25/2025 | ±4.3% | +0.7% | over-priced |
| 01/31/2025 | ±5.2% | +0.4% | over-priced |
| 04/29/2024 | ±3.0% | +0.4% | over-priced |
| 01/29/2024 | ±3.4% | +0.8% | over-priced |
| 10/23/2023 | ±3.8% | -0.1% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q4 FY2026 | $1.81 | $6.7B | $2.3B |
| Q3 FY2026 | $1.45 | $5.8B | $1.8B |
| Q2 FY2026 | $1.26 | $5.3B | $1.6B |
| Q1 FY2026 | $1.24 | $5.3B | $1.6B |
Lam Research Corp (LRCX) reports in 38 days, with the next report estimated for 10/20/2026. Across the last 8 reports, options priced an average ±4.0% earnings move while the stock actually moved 1.4% on average — the market has systematically over-priced LRCX's earnings risk. Fundamentals into the print: EPS up 35.1% year-over-year, revenue up 30.0%. QuantLogix's live 5-factor engine currently reads LRCX as a neutral at 53/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →